The effects of a PPARα agonist on myocardial damage in obese diabetic mice with heart failure

International Heart Journal

Volumn 51, Issue 3, 2010, Pages 199-206

  Chen, Rui ^a,b   Liang, Fengxia ^a,d   Morimoto, Shigeto ^a   Li, Qian ^c   Moriya, Junji ^a   Yamakawa, Jun ichi ^a   Takahashi, Takashi ^a   Iwai, Kunimitsu ^a   Kanda, Tsugiyasu ^a  

^a KANAZAWA MEDICAL UNIVERSITY   (Japan)

^b Union Hospital   (China)

^c HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^d HUBEI UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Adiponectin; Tumor necrosis factor (TNF ); Uncoupling protein 3 (UCP3)

Indexed keywords

ADIPONECTIN; DIMETHYL SULFOXIDE; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PIRINIXIC ACID; TUMOR NECROSIS FACTOR ALPHA; UNCOUPLING PROTEIN 3; MITOCHONDRIAL PROTEIN; PEROXISOME PROLIFERATOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PYRIMIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DIABETIC OBESITY; DISEASE SEVERITY; ENCEPHALOMYOCARDITIS VIRUS; FEMALE; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; HEART FAILURE; HEART MUSCLE INJURY; HEART PROTECTION; MORTALITY; MOUSE; MYOCARDITIS; NONHUMAN; PRIORITY JOURNAL; SURVIVAL RATE; WEIGHT REDUCTION; ANIMAL; DISEASE MODEL; DRUG POTENTIATION; HEART MUSCLE; METABOLISM; MOUSE MUTANT; NON INSULIN DEPENDENT DIABETES MELLITUS; NONOBESE DIABETIC MOUSE; OBESITY; PATHOLOGY; PHYSIOLOGY;

ADIPONECTIN; ANIMALS; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; FEMALE; HEART FAILURE; MICE; MICE, INBRED NOD; MICE, OBESE; MITOCHONDRIAL PROTEINS; MYOCARDIUM; OBESITY; PEROXISOME PROLIFERATORS; PPAR ALPHA; PYRIMIDINES;

EID: 77954973133     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.51.199     Document Type: Article

References (30)

1. Brown JD, Plutzky J. Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets. Circulation 2007; 115: 518-33. (Review)
2. Takano H, Nagai T, Asakawa M, et al. Peroxisome proliferator-activated receptor activators inhibit lipopolysaccharide-induced tumor necrosis factor-alpha expression in neonatal rat cardiac myocytes. Circ Res 2000; 87: 596-602.
3. Tsuchida A, Yamauchi T, Takekawa S, et al. Peroxi some proliferator-activated receptor (PPAR) alpha activation increases adiponectin receptors and reduces obesity-related inflammation in adipose tissue: comparison of activation of PPARalpha, PPARgamma, and their combination. Diabetes 2005; 54: 3358-70.
4. Ichihara S, Obata K, Yamada Y, et al. Attenuation of cardiac dysfunction by a PPAR-alpha agonist is associated with down-regulation of redox-regulated transcription factors. J Mol Cell Cardiol 2006; 41: 318-29.
5. Keech A, Simes RJ, Barter P, et al. Effects of long-term fenof-brate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366: 1849-61.
6. Boudina S, Sena S, Theobald H, et al. Mitochondrial energetics in the heart in obesity-related diabetes: direct evidence for increased uncoupled respiration and activation of uncoupling proteins. Diabetes 2007; 56: 2457-66.
7. Pedraza N, Rosell M, Villarroya J, et al. Developmental and tissue-specifc involvement of peroxisome proliferator-activat-ed receptor-alpha in the control of mouse uncoupling protein-3 gene expression. Endocrinology 2006; 147: 4695-704.
8. Boehm EA, Jones BE, Radda GK, Veech RL, Clarke K. Increased uncoupling proteins and decreased effciency in palmi-tate-perfused hyperthyroid rat heart. Am J Physiol Heart Circ Physiol 2001; 280: H977-83.
9. Murray AJ, Panagia M, Hauton D, Gibbons GF, Clarke K. Plasma free fatty acids and peroxisome proliferator-activated receptor alpha in the control of myocardial uncoupling protein levels. Diabetes 2005; 54: 3496-502.
10. Bahrami H, Bluemke DA, Kronmal R, et al. Novel metabolic risk factors for incident heart failure and their relationship with obesity: the MESA (Multi-Ethnic Study of Atherosclerosis) study. J Am Coll Cardiol 2008; 51: 1775-83.
11. Matsumori A, Sasayama S. Immunomodulating agents for the management of heart failure with myocarditis and cardiomyopathy-lessons from animal experiments. Eur Heart J 1995; 16: 140-3. (Review)
12. Yu F, Chen R, Takahashi T, et al. Candesartan improves myo-cardial damage in obese mice with viral myocarditis and induces cardiac adiponectin. Int J Cardiol 2008; 129: 414-21.
13. Takahashi T, Yu F, Saegusa S, et al. Impaired expression of cardiac adiponectin in leptin-defcient mice with viral myocarditis. Int Heart J 2006; 47: 107-23.
14. Kanda T, McManus JE, Nagai R, et al. Modifcation of viral myocarditis in mice by interleukin-6. Circ Res 1996; 78: 848-56.
15. Matsumori A, Kawai C. An experimental model for congestive heart failure after encephalomyocarditis virus myocarditis in mice. Circulation 1982; 65: 1230-5.
16. Kanazawa K, Kawashima S, Mikami S, et al. Endothelial constitutive nitric oxide synthase protein and mRNA increased in rabbit atherosclerotic aorta despite impaired endothelium-dependent vascular relaxation. Am J Pathol 1996; 148: 1949-56.
17. Mann DL. Infammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res 2002; 91: 988-98. (Review)
18. Niu J, Azfer A, Deucher MF, Goldschmidt-Clermont PJ, Kolat-tukudy PE. Targeted cardiac expression of soluble Fas prevents the development of heart failure in mice with cardiac-specifc expression of MCP-1. J Mol Cell Cardiol 2006; 40: 810-20.
19. Mann DL. Tumor necrosis factor and viral myocarditis: the fne line between innate and inappropriate immune responses in the heart. Circulation 2001; 103: 626-9.
20. Lopaschuk GD, Folmes CD, Stanley WC. Cardiac energy metabolism in obesity. Circ Res 2007; 101: 335-47. (Review)
21. Shibata R, Ouchi N, Ito M, et al. Adiponectin-mediated modulation of hypertrophic signals in the heart. Nat Med 2004; 10: 1384-9.
22. Takahashi T, Saegusa S, Sumino H, et al. Adiponectin, T-cad-herin and tumor necrosis factor-alpha in damaged cardiomyo-cytes from autopsy specimens. J Int Med Res 2005; 33: 236-44.
23. Pedraza N, Rosell M, Villarroya J, et al. Developmental and tissue-specifc involvement of peroxisome proliferator-activated receptor-alpha in the control of mouse uncoupling protein-3 gene expression. Endocrinology 2006; 147: 4695-704.
24. Neubauer S, Horn M, Cramer M, et al. Myocardial phospho-creatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy. Circulation 1997; 96: 2190-6.
25. Baranowski M, Blachnio-Zabielska A, Gorski J. Peroxisome proliferator-activated receptor alpha activation induces unfavourable changes in fatty acid composition of myocardial phospholipids. J Physiol Pharmacol 2009; 60: 13-20.
26. Finck BN, Han X, Courtois M, et al. A critical role for PPA-Ralpha-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: modulation by dietary fat content. Proc Natl Acad Sci U S A 2003; 100: 1226-31.
27. Panzram G. Mortality and survival in type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1987; 30: 123-31. (Review)
28. Kenchaiah S, Evans JC, Levy D, et al. Obesity and the risk of heart failure. N Engl J Med 2002; 347: 305-13.
29. Buroker NE, Barboza J, Huang JY. The IkappaBalpha gene is a peroxisome proliferator-activated receptor cardiac target gene. FEBS J 2009; 276: 3247-55.
30. Caglayan E, Stauber B, Collins AR, et al. Differential roles of cardiomyocyte and macrophage peroxisome proliferator-activated receptor gamma in cardiac fibrosis. Diabetes 2008; 57: 2470-9.